[go: up one dir, main page]

UA99489C2 - Crystalline chemotherapeutic agent - Google Patents

Crystalline chemotherapeutic agent

Info

Publication number
UA99489C2
UA99489C2 UAA201006027A UAA201006027A UA99489C2 UA 99489 C2 UA99489 C2 UA 99489C2 UA A201006027 A UAA201006027 A UA A201006027A UA A201006027 A UAA201006027 A UA A201006027A UA 99489 C2 UA99489 C2 UA 99489C2
Authority
UA
Ukraine
Prior art keywords
chemotherapeutic agent
crystalline
crystalline chemotherapeutic
indazol
methylphenyl
Prior art date
Application number
UAA201006027A
Other languages
English (en)
Inventor
Майкл Дж. Розема
Original Assignee
Эбботт Леборетриз
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эбботт Леборетриз filed Critical Эбботт Леборетриз
Publication of UA99489C2 publication Critical patent/UA99489C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
UAA201006027A 2007-10-19 2008-10-16 Crystalline chemotherapeutic agent UA99489C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98125307P 2007-10-19 2007-10-19

Publications (1)

Publication Number Publication Date
UA99489C2 true UA99489C2 (en) 2012-08-27

Family

ID=40174807

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201006027A UA99489C2 (en) 2007-10-19 2008-10-16 Crystalline chemotherapeutic agent

Country Status (18)

Country Link
US (1) US7960564B2 (ru)
EP (1) EP2195301A1 (ru)
JP (1) JP2011500707A (ru)
KR (1) KR20100085987A (ru)
CN (1) CN101827824B (ru)
AU (1) AU2008312533A1 (ru)
BR (1) BRPI0818334A2 (ru)
CA (1) CA2699354A1 (ru)
CO (1) CO6280484A2 (ru)
CR (1) CR11443A (ru)
DO (1) DOP2010000112A (ru)
EC (1) ECSP10010176A (ru)
GT (1) GT201000100A (ru)
MX (1) MX2010004290A (ru)
PA (1) PA8800601A1 (ru)
RU (1) RU2010119919A (ru)
UA (1) UA99489C2 (ru)
WO (1) WO2009052230A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140031769A1 (en) 2010-11-19 2014-01-30 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
EP2739252A4 (en) 2011-08-05 2015-08-12 Forsight Vision4 Inc DISPOSAL OF SMALL MOLECULES THROUGH AN IMPLANTABLE THERAPEUTIC DEVICE
AU2014236455B2 (en) 2013-03-14 2018-07-12 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
CA2957548A1 (en) 2014-08-08 2016-02-11 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0410745A (pt) * 2003-05-22 2006-06-27 Abbott Lab inibidores de indazol, benzisoxazol e benzisotiazol quinase
US7297709B2 (en) * 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
DE102005033100B3 (de) * 2005-07-15 2007-01-25 Sanofi-Aventis Deutschland Gmbh Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, diese Verbindung enthaltene Arzneimittel und Verfahren zu deren Herstellung
WO2007015569A1 (ja) * 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を予測する方法
US9006240B2 (en) * 2005-08-02 2015-04-14 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
EP1959926A1 (en) 2005-10-25 2008-08-27 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
EP1962803A1 (en) * 2005-12-23 2008-09-03 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US20070173538A1 (en) * 2005-12-23 2007-07-26 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
EP2089003A1 (en) * 2006-11-09 2009-08-19 Abbott GmbH & Co. KG Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor

Also Published As

Publication number Publication date
RU2010119919A (ru) 2011-11-27
US7960564B2 (en) 2011-06-14
BRPI0818334A2 (pt) 2017-05-16
PA8800601A1 (es) 2009-05-15
AU2008312533A1 (en) 2009-04-23
EP2195301A1 (en) 2010-06-16
GT201000100A (es) 2012-04-12
CA2699354A1 (en) 2009-04-23
MX2010004290A (es) 2010-04-30
CR11443A (es) 2010-09-27
US20090124815A1 (en) 2009-05-14
JP2011500707A (ja) 2011-01-06
ECSP10010176A (es) 2010-06-29
CN101827824B (zh) 2012-10-03
WO2009052230A1 (en) 2009-04-23
DOP2010000112A (es) 2010-07-15
KR20100085987A (ko) 2010-07-29
CO6280484A2 (es) 2011-05-20
CN101827824A (zh) 2010-09-08

Similar Documents

Publication Publication Date Title
DK2092065T3 (da) Antisense-forbindelser
TW200738242A (en) Dihydropteridinones in the treatment of respiratory diseases
TW200612905A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TW200611702A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
SI2205244T1 (sl) Postopki dajanja N-(5-terc.-butil-izoksazol-3-il)-N'-(4-(7-(2-morfolin- 4-il-etoksi-)imidazo-2,1-b)-(1,3)-benzotiazol-2-il)-fenil)sečnine za zdravljenje proliferativne bolezni
MA32717B1 (fr) Sels de n-[6-cis- (2.6-dimethylmorpholin-4-yl)pyridin-3-yl)-2-methyl-4'- (trifluoromethoxy)- [1.1'-biphenyl]-3-carboxamide
UA99489C2 (en) Crystalline chemotherapeutic agent
UA99490C2 (en) Crystalline chemotherapeutic agent
MX2010004288A (es) Productos quimioterapeuticos cristalinos.
UA99746C2 (ru) Кристаллическое химиотерапевтическое средство на основе индазола
UA99487C2 (xx) Кристалічний хіміотерапевтичний засіб$кристаллическое химиотерапевтическое средство
NO20071889L (no) Middel for profylakse eller behandling av stoffskiftesyndrom.
TW200628168A (en) Use of organic compounds
PL1904511T3 (pl) Homogemcytabiny
UA84886C2 (en) N-[2'-hydroxy-3'-(n'-camphorimide)propyl]-exo-5-aminomethylbicyclo[2.2.1]hept-2-en hydrochloride having analgetic, tranquilizing and antihypoxic action
UA27127U (en) Use of n-(4-difluoromethoxyphenyl) -n'-1,2,2-trimethylpropyl-n"-cyanoguanidine (flocalin) as agent stimulating cerebral blood circulation